Fred Aslan, Artiva Biotherapeutics CEO
July 1, 2024 04:34 AM EDTUpdated 06:41 AM
Financing
Startups

Arti­va re­files for IPO three years af­ter orig­i­nal plans in a vast­ly dif­fer­ent en­vi­ron­ment

Kyle LaHucik

Senior Reporter

Arti­va Bio­ther­a­peu­tics, a clin­i­cal-stage NK cell ther­a­py biotech, is try­ing again for the pub­lic mar­kets, it re­vealed Fri­day af­ter­noon in an SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

As con­fi­dence falls, bio­phar­ma com­pa­nies take pre­cau­tions with Chi­nese part­ner­ships, sur­vey finds

J&J and Leg­end say Carvyk­ti im­proved sur­vival in ear­li­er-line mul­ti­ple myelo­ma

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Fol­low­ing a piv­otal tri­al fail and lay­offs, Ovid finds it­self in a fa­mil­iar spot

'Op­ti­miz­ing R&D struc­ture is al­so on the hori­zon, with­out ex­cep­tion,' new Sum­it­o­mo Phar­ma CEO says

A service from the Financial Times